Urinary Bladder
- Home
- Cancer Infomation
Urinary Bladder Cancer
Urinary bladder cancer is a significant global health burden, primarily presenting as Urothelial Carcinoma (UC)—formerly known as transitional cell carcinoma—in over 90% of cases.While urothelial carcinoma accounts for the vast majority of cases, other rare histological types include squamous cell carcinoma (often associated with chronic irritation or schistosomiasis) and adenocarcinoma.
Etiology & Risk Factors
The development of bladder cancer is typically a multi-hit process involving chronic exposure to urinary carcinogens and specific genomic instabilities.
Environmental & Lifestyle Triggers:
- Tobacco Smoking: The most significant risk factor, associated with 50% of all cases.
- Occupational Exposures: Historic and chronic exposure to aromatic amines, polycyclic aromatic hydrocarbons (PAHs), and dyes used in the rubber, leather, and textile industries.
- Schistosomiasis: chronic infection with Schistosoma haematobium is a leading cause of Squamous Cell Carcinoma of the bladder.
- Chemical/Iatrogenic Exposure: Long-term use of cyclophosphamide or ingestion of arsenic-contaminated water.
Genetic Predispositions:
- FGFR3 Mutations
- TP53 and RB1 Alterations: Often associated with high-grade, muscle-invasive disease and Carcinoma in Situ (CIS).
- Lynch Syndrome: Patients with germline mutations in DNA mismatch repair (MMR) genes carry an elevated risk of upper tract urothelial carcinoma (UTUC) and bladder cancer.
Clinical Manifestations
Symptoms often mimic benign urological conditions, which can lead to diagnostic delays.
Early-Stage Symptoms
- Painless Gross Hematuria: The hallmark symptom (present in ~80% of patients). Even a single episode of visible blood in the urine warrants a full workup.
- Microscopic Hematuria: Found incidentally during routine urinalysis.
- Irritative Voiding Symptoms: Frequency, urgency, and dysuria—often more common in Carcinoma in Situ (CIS).
Advanced-Stage Symptoms
- Flank Pain: Suggestive of ureteral obstruction or hydronephrosis.
- Pelvic or Bone Pain: Indicative of local invasion or metastatic spread.
- Lower Extremity Edema: Resulting from lymphatic obstruction by regional lymph node metastases.
- Systemic Signs: Unintentional weight loss, fatigue, and anemia.
Diagnostic Workup
The diagnostic pathway utilizes a “multi-omic” approach to reduce the frequency of invasive procedures while maintaining high sensitivity.
- Cystoscopy and TURBT: The definitive gold standard. Transurethral Resection of Bladder Tumor (TURBT) provides essential histological data regarding tumor type, grade, and depth of invasion (presence of muscularis propria in the specimen is mandatory for accurate staging).
- Urine Cytology: High specificity for high-grade tumors and CIS, though sensitivity for low-grade lesions remains limited.
- Biomarkers & Liquid Biopsies:
- Urine-based DNA testing (e.g., UroVysion FISH): Used to monitor recurrence.
- ctDNA (Circulating Tumor DNA): liquid biopsies are increasingly used post-surgery to detect Minimal Residual Disease (MRD) and predict relapse before it is visible on imaging.
Common Investigations
Imaging Modalities & Rationale
- CT Urography (CTU): The standard initial imaging. It evaluates the entire urinary tract (kidneys, ureters, and bladder) to rule out synchronous upper tract tumors.
- Multiparametric MRI (mpMRI): Utilizes the VI-RADS (Bladder Imaging-Reporting and Data System) score. This is superior to CT for differentiating between T1 (non-muscle invasive) and T2 (muscle invasive) disease, aiding in the decision for bladder preservation.
- FDG PET-CT: While not routine for early-stage disease, it is the preferred modality for initial staging of MIBC to detect occult nodal or distant metastasis (M1) and for evaluating treatment response after systemic therapy.
Clinical Manifestations
Early-stage prostate cancer is characteristically asymptomatic. Most cases are now identified via PSA (Prostate-Specific Antigen) screening before physical symptoms appear.
1. Surgery
- TURBT: The primary treatment for NMIBC , often followed by intravesical therapy (BCG or Gemcitabine).
- Radical Cystectomy (RC): The standard for MIBC . Includes removal of the bladder, regional lymph nodes, and adjacent organs.
- Approach: Robotic-assisted Radical Cystectomy (RARC) is now the preferred minimal-invasive approach in high-volume centers due to reduced blood loss and faster recovery.
- Urinary Diversion: Options include the Ileal Conduit (incontinent) or Orthotopic Neobladder (continent), depending on patient age, comorbidities, and urethral margin status.
2. Radiotherapy
- Trimodality Therapy (TMT): A bladder-sparing alternative for very selected MIBC patients. It involves a maximal TURBT followed by concurrent chemoradiation.
- Techniques: IMRT (Intensity-Modulated Radiation Therapy) and IGRT (Image-Guided Radiation Therapy) are used to limit toxicity to the bowel and rectum.
3. Systemic Therapy
- Neoadjuvant Chemotherapy (NAC): Cisplatin-based regimens (e.g., ddMVAC or Gem/Cis) are the standard of care prior to cystectomy for MIBC, significantly improving overall survival.
- Immunotherapy: Checkpoint inhibitors (e.g., Pembrolizumab, Nivolumab) are used for BCG-unresponsive NMIBC and as first-line or maintenance therapy in metastatic disease.
- Antibody-Drug Conjugates (ADCs): Enfortumab vedotin (targeting Nectin-4) has revolutionized the treatment of advanced urothelial carcinoma, often used in combination with immunotherapy.
Emerging Therapies
- Personalized Neoantigen Vaccines: Clinical trials are now integrating customized vaccines alongside immunotherapy to prime the immune system against patient-specific bladder cancer mutations.
- AI-Enhanced Pathology: AI algorithms are now used to analyze TURBT slides to predict the likelihood of progression to muscle-invasive disease with higher accuracy than human grading alone.
- Next-Gen ADCs: New molecules targeting HER2 and Trop-2 are expanding options for patients who fail standard checkpoint inhibitors.
Medical Disclaimer
This guide is for professional informational purposes and does not replace clinical judgment.
Treatment decisions should be made by a multidisciplinary tumor board.
Always refer to the latest NCCN or institutional guidelines for specific patient management.